Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

Neurology

Volumn 54, Issue 10, 2000, Pages 1916-1921

  Hurtig, Howard I ^b   Trojanowski, J Q ^b   Galvin, J ^a   Ewbank, D ^b   Schmidt, M L ^b   Lee, V M Y ^b   Clark, C M ^b   Glosser, G ^b   Stern, M B ^b   Gollomp, S M ^b   Arnold, S E ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

AD; Dementia; Lewy body; PD; Ubiquitin; Synuclein

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWY BODY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0034705015     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.10.1916     Document Type: Article

References (51)

1. Pollock M, Hornabrook RW. Prevalence, natural history and dementia of Parkinson's disease. Brain 1966;89:429-448.
2. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992;49:492-497.
3. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson's disease. Arch Neurol 1996; 53:538-542.
4. Greenfield JG, Bosanquet FD. The brain stem lesions in parkinsonism. J Neurol Neurosurg Psychiatry 1953;16:213-226.
5. Gibb WRG, Scott T, Lees AJ. Neuronal inclusions of Parkinson's disease. Mov Disord 1991;6:2-11.
6. Lennox G, Lowe J, Morrell K, et al. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71.
7. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
8. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-244.
9. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy body and senile changes of varying degree. A new disease? Clin Neuropathol 1984;3:185-192.
10. McKieth IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium of DLB international workshop. Neurology 1996;47:1113-1124.
11. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop. Neurology 1999;53:902-905.
12. Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81-88.
13. Perry RH, Irving D, Blessed G, et al. Senile dementia of Lewy body type. A clinically and neuropathologically distinct type of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
14. Ince P, Irving D, McArthur F, Perry RH. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type. Parkinson's disease and non-demented elderly control patients. J Neurol Sci 1991;106: 142-152.
15. Perl DP, Olanow CW, Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 1998;44(suppl 1):S19-S31.
16. Jellinger KA. Paulus W. Clinico-pathological correlations in Parkinson's disease. Clin Neurol Neurosurg 1992;94(suppl): S86-S88.
17. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
18. Spillantini MG, Schmidt ML, Lee VM-Y, et al. α-Synuclein in Lewy bodies. Nature 1997;388:232-233.
19. Baba M, Nakajo S, Tu P-H, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884.
20. Giasson B, Uryu K, Trojanowski JQ, et al. Mutant and wild-type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274: 7619-7622.
21. Ward CD, Gibb WR. Research diagnosis criteria for Parkinson's disease. Adv Neurol 1990;53:245-249.
22. Schmidt ML, Lee VM, Hurtig HI, Trojanowski JQ. Properties of antigenic determinants that distinguish neurofibrillary tangles in progressive supranuclear palsy and Alzheimer's disease. Lab Invest 1988;59:460-466.
23. Hoehn MMM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983;19(suppl):253-264.
24. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia and Alzheimer disease: clinicopathological correlations. Ann Neurol 1980;7:329-335.
25. Yoshimura M. Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease. Eur Neurol 1988; 28:29-35.
26. Simuni TS, Stern MB. Does levodopa accelerate Parkinson's disease? Drugs Aging 1999;14:399-408.
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-148.
28. deVos RA, Jansen EN, Stan FE, et al. Lewy body disease: clinico-pathological correlations in 18 consecutive case of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 1995;97:13-22.
29. Sugiyama H, Hainfellner JA, Yoshimura M, Budka H. Neocortical changes in Parkinson's disease, revisited. Clin Neuropathol 1994;13:55-59.
30. Santacruz K, Pahwa R, Lyons K, et al. Lewy body, neurofibrillary and plaque pathology in Parkinson's disease patients with and without dementia. Neurology 1999;52(suppl 2):476-477. Abstract.
31. Irizarry MC, Growdon JW, Gomez Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57:334-337.
32. Tu P-H, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann Neurol 1998;44: 415-422.
33. Lippa CF, Schmidt ML, Lee VM-Y, Trojanowski JQ. Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999;45: 353-357.
34. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon J, Hyman BT. Clinical and quantitative pathological correlates of dementia with Lewy bodies. Neurology 1999;52(suppl 2):478-479. Abstract.
35. Narhi L, Wood SJ, Steavenson S, et al. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 1999;274:9843-9846.
36. Brown DF, Dababo MA, Bigio EH, Risser RC. Neuropathological evidence that the Lewy body versus Alzheimer's disease represents co-existence of Alzheimer's disease and Parkinson's disease. J Neuropathol Exp Neurol 1998;57:39-46.
37. Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm 1997;51(suppl): 57-82.
38. Xuereb JH, Tomlinson E, Irving D, et al. Cortical and subcortical pathology in Parkinson's disease: relationship to Parkinson dementia. Adv Neurol 1990;53:35-40.
39. Kachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
40. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) II: standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-486.
41. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci 1968;7:331-356.
42. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970;11:205-242.
43. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease from the National Institute on Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56:1095-1097.
44. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-258.
45. Mattila PM, Royatta M, Torikka H, et al. Cortical Lewy body and Alzheimer type changes in patients with Parkinson's disease. Acta Neuropathol 1998;95:576-582.
46. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52.
47. Lennox G. Dementia with Lewy bodies. In: Growdon JH, Rossor M, eds. The dementias. Boston: Butterworth-Heinemann, 1998:67-80.
48. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque only Alzheimer's disease is usually the Lewy Body variant and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
49. Quinn NP, Rossor MN, Marsden CD. Dementia and Parkinson's disease - pathological and neurochemical considerations. Br Med Bull 1986;42:86-90.
50. Dickson DW, Ruan D, Crystal HA, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease; light and electron microscopic immunocytochemistry of CA 2-3 neurites specific to DLBD. Neurology 1991;41:1402-1409.
51. Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998;55:969-978.